Good results for Biotech's three-dose regimen in infants.
Monkeypox draws attention to vaccine producers.
Biontech $BNTX (BioNTech SE) and Pfizer $PFE (Pfizer) have presented data on their three-dose study in children between six months and five years of age - the only age group for which no covid vaccine has yet been officially approved. At the very low dose of three micrograms per shot, the vaccine elicited a robust immune response, with initial estimates of 80 percent efficacy against symptomatic disease (source: investors.biontech.de/news-releases/news-release-details/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune).
By comparison, Moderna's two-dose regimen in a comparable age group had 37 to 51 percent efficacy. Moderna's infant vaccine contains 25 micrograms of mRNA. On June 15, the FDA's advisory panel will discuss U.S. approval of both manufacturers' vaccines, and the day after that, Moderna's application for six- to 17-year-olds. The vaccination rate for children up to eleven is low in Germany and the USA.
With monkeypox, another disease is currently making headlines. Smallpox vaccination (compulsory in Germany until 1976) is also effective against monkeypox, and the UK already offers it to close contacts of infected persons. Bavarian Nordic (not tradable on eToro) and Emergent Biosolutions $EBS (Emergent BioSolutions Inc) produce approved vaccines and can now expect additional orders, albeit of rather limited volume.
𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: I own $BNTX stock. This is not investment advice.